Literature DB >> 19003278

Dexamethasone inhibits bone resorption by indirectly inducing apoptosis of the bone-resorbing osteoclasts via the action of osteoblastic cells.

S Warabi1, Y Tachibana, M Kumegawa, Y Hakeda.   

Abstract

Although glucocorticoids (GCs) are physiologically essentialfor bone metabolism, it is generally accepted that high dosesof GCs cause bone loss through a combination of decreased boneformation and increased bone resorption. However, the actionof GCs on mature osteoclasts remains contradictory. In thisstudy, we have examined the effect of GCs on osteoclasticbone-resorbing activity and osteoclast apoptosis, by using twodifferent cell types, rabbit unfractionated bone cells andhighly enriched mature osteoclasts (>95% of purity).Dexamethasone (Dex, 10(-10)-10(-7) M) inhibited resorption pit formation on a dentine slice by the unfractionated bone cells in a dose- and time-dependent manner.However, Dex had no effect on the bone-resorbing activity of the isolated mature osteoclasts. When the isolated osteoclastswere co-cultured with rabbit osteoblastic cells, the osteoclastic bone resorption decreased in response to Dex,dependent on the number of osteoblastic cells. Like the effecton the bone resorption, Dex induced osteoclast apoptosis in cultures of the unfractionated bone cells, whereas it did not promote the apoptosis of the isolated osteoclasts. An inhibitorof caspases, Z-Asp-CH2-DCB attenuated both the inhibitory effecton osteoclastic bone resorption and the stimulatory effect onthe osteoclast apoptosis. In addition, the osteoblastic cellswere required for the osteoclast apoptosis induced by Dex. These findings indicate that the main target cells of GCs arenon-osteoclastic cells such as osteoblasts and that GCsindirectly inhibit bone resorption by inducing apoptosis ofthe mature osteoclasts through the action of non-osteoclasticcells. This study expands our knowledge about the multifunctional roles of GCs in bone metabolism.

Entities:  

Year:  2001        PMID: 19003278      PMCID: PMC3466617          DOI: 10.1023/A:1008159332152

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  42 in total

1.  Glucocorticoids promote development of the osteoblast phenotype by selectively modulating expression of cell growth and differentiation associated genes.

Authors:  V Shalhoub; D Conlon; M Tassinari; C Quinn; N Partridge; G S Stein; J B Lian
Journal:  J Cell Biochem       Date:  1992-12       Impact factor: 4.429

2.  Determination of the capacity for proliferation and differentiation of osteoprogenitor cells in the presence and absence of dexamethasone.

Authors:  C G Bellows; J N Heersche; J E Aubin
Journal:  Dev Biol       Date:  1990-07       Impact factor: 3.582

3.  Effects of glucocorticoids on fetal rat bone collagen synthesis in vitro.

Authors:  J W Dietrich; E M Canalis; D M Maina; L G Raisz
Journal:  Endocrinology       Date:  1979-03       Impact factor: 4.736

4.  The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells.

Authors:  N Udagawa; N Takahashi; T Akatsu; T Sasaki; A Yamaguchi; H Kodama; T J Martin; T Suda
Journal:  Endocrinology       Date:  1989-10       Impact factor: 4.736

5.  A simple method to assess osteoclast-mediated bone resorption using unfractionated bone cells.

Authors:  Y Takada; M Kusuda; K Hiura; T Sato; H Mochizuki; Y Nagao; M Tomura; M Yahiro; Y Hakeda; H Kawashima
Journal:  Bone Miner       Date:  1992-06

6.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

7.  Interactions between growth hormone and dexamethasone in skeletal growth and bone structure of the young mouse.

Authors:  A Altman; Z Hochberg; M Silbermann
Journal:  Calcif Tissue Int       Date:  1992-10       Impact factor: 4.333

8.  Opposing influences of glucocorticoid and retinoic acid on transcriptional control in preosteoblasts.

Authors:  K W Ng; S S Manji; M F Young; D M Findlay
Journal:  Mol Endocrinol       Date:  1989-12

9.  Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients.

Authors:  J S Adams; T O Wahl; B P Lukert
Journal:  Metabolism       Date:  1981-03       Impact factor: 8.694

10.  Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts.

Authors:  T Kameda; H Mano; T Yuasa; Y Mori; K Miyazawa; M Shiokawa; Y Nakamaru; E Hiroi; K Hiura; A Kameda; N N Yang; Y Hakeda; M Kumegawa
Journal:  J Exp Med       Date:  1997-08-18       Impact factor: 14.307

View more
  4 in total

1.  Sustained release of adiponectin improves osteogenesis around hydroxyapatite implants by suppressing osteoclast activity in ovariectomized rabbits.

Authors:  En Luo; Jing Hu; Chongyun Bao; Yunfeng Li; Qisheng Tu; Dana Murray; Jake Chen
Journal:  Acta Biomater       Date:  2011-10-25       Impact factor: 8.947

Review 2.  Enhancing regenerative approaches with nanoparticles.

Authors:  Sabine van Rijt; Pamela Habibovic
Journal:  J R Soc Interface       Date:  2017-04       Impact factor: 4.118

Review 3.  Therapeutic Nanoparticles and Their Targeted Delivery Applications.

Authors:  Abuzer Alp Yetisgin; Sibel Cetinel; Merve Zuvin; Ali Kosar; Ozlem Kutlu
Journal:  Molecules       Date:  2020-05-08       Impact factor: 4.411

Review 4.  Use of in vitro bone models to screen for altered bone metabolism, osteopathies, and fracture healing: challenges of complex models.

Authors:  Sabrina Ehnert; Helen Rinderknecht; Romina H Aspera-Werz; Victor Häussling; Andreas K Nussler
Journal:  Arch Toxicol       Date:  2020-09-10       Impact factor: 5.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.